Everyday Health on MSN

Obstructive vs. Nonobstructive Hypertrophic Cardiomyopathy (HCM): What Your Diagnosis Means for Treatment and Lifestyle

Learn the key differences between obstructive and nonobstructive HCM, including how your specific diagnosis can impact ...
Business Insider

MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy PatientsTopline Data Anticipated in ...

SOUTH SAN FRANCISCO, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of ...
MedCity News

Startup HAYA Hauls In $65M to Shed Light on the Dark Genome With a Lead Drug for Heart Failure

Many drugs available and in development work by targeting proteins, an approach that comes with limitations. For one, proteins are not the root cause of disease, said Samir Ounzain, co-founder and CEO ...
Fierce Pharma

Bristol Myers Squibb paves way for expansion of Camzyos to adolescent patients

Camzyos, which works by blocking the actin-myosin interactions responsible for HCM and, in effect, relaxing the heart, bears ...
Nasdaq

Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic ...
Business Wire

Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the dosing of the first patient in the Phase 2 ...